Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.52 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5012082 | 0.89 | ADORA1 (0.48) | NTRK1NTRK2MEN1KMT2AMAPK14 | |
| SCHEMBL5007743 | 0.87 | CLCN2 (0.51) | MAPK14MAPK13MAPK12MAPK11GFER | |
| SCHEMBL5010659 | 0.83 | MAPK14 (0.64) | NTRK1MEN1KMT2AMAPK14MAPK13 | |
| SCHEMBL27617934 | 0.82 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11GFER | |
| SCHEMBL5005583 | 0.81 | GFER (0.53) | MAPK14MAPK13MAPK12MAPK11GFER | |
| SCHEMBL5010672 | 0.81 | MAPK14 (0.59) | MEN1KMT2AMAPK14MAPK13MAPK12 | |
| SCHEMBL5007721 | 0.79 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11GFER | |
| SCHEMBL5012181 | 0.79 | ADORA1 (0.51) | MEN1KMT2AMAPK14MAPK13MAPK12 | |
| SCHEMBL5008768 | 0.79 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11GFER | |
| SCHEMBL28757654 | 0.78 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | claimed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | claimed |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | claimed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | NTRK1 4337/4885NTRK2 2371/4885MEN1 4148/4885 |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | NTRK1 4337/4885NTRK2 2371/4885MEN1 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.